Cipla Emerges as Domestic Contender in Anti-Obesity Market with Yurpeak We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Eli Lilly‘s weight-loss therapy Mounjaro became India’s top-selling drug by value in October, data showed on Friday, overtaking GSK’s widely used antibiotic Augmentin, as demand surges in the world’s most populous nation. The U.S. drugmaker’s popular injectable therapy raked in 1 billion rupees ($11.38 million) in October, research firm Pharmarack said. That outpaced Augmentin sales…
Pfizer is closing in on a potential $7.3 billion takeover of anti-obesity drug developer Metsera, the Financial Times reported on Sunday, citing unidentified sources. Pfizer will pay Metsera $47.50 in cash per share and a further $22.50 if certain performance milestones are met, the newspaper said, adding that the announcement could come as early as…
Sales of Danish drugmaker Novo Nordisk‘s Wegovy and U.S. rival Eli Lilly’s Mounjaro in India doubled in July from a month earlier, data from research firm Pharmarack showed on Thursday. Demand for the blockbuster anti-obesity drugs, which help control blood sugar and slow digestion, has been on an upswing in the world’s most populous nation….